Saltar al contenido
Merck

Heterologous protein production capacity of mammalian cells cultivated as monolayers and microtissues.

Biotechnology and bioengineering (2005-10-29)
Carlota Diaz Sanchez-Bustamante, Jens M Kelm, Barbara Mitta, Martin Fussenegger
RESUMEN

A precise understanding of processes managing heterologous protein production in vitro and in vivo is essential for the manufacture of sophisticated biopharmaceuticals as well as for future gene therapy and tissue engineering initiatives. Capitalizing on the gravity-enforced self-assembly of monodispersed cells into coherent (multicellular) microtissues we studied heterologous protein production of microtissues and monolayers derived from cell lines and primary cells engineered/transduced for (i) constitutive, (ii) proliferation-controlled, (iii) macrolide-, or (iv) gas-inducible expression of the human placental secreted alkaline phosphatase (SEAP) and of the Bacillus stearothermophilus-derived secreted alpha-amylase (SAMY). Specific productivity of cells assembled in microtissues was up to 20-fold higher than isogenic monolayer cultures. Diffusion across microtissues could be further increased by HUVEC-mediated vascularization. As well as higher specific protein productivities, microtissues were also more efficient than monolayer cultures in assembling transgenic lentiviral particles. Our results showed that mammalian cells embedded in a tissue-like three-dimensional (3D) microenvironment exhibit increased production capacity. This observation should be considered for gene therapy and tissue engineering scenarios as well as for biopharmaceutical manufacturing.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
L-histidina monohydrochloride monohydrate, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-101.0%